BR112021022363A2 - Composições e métodos para fabricação de células t - Google Patents

Composições e métodos para fabricação de células t

Info

Publication number
BR112021022363A2
BR112021022363A2 BR112021022363A BR112021022363A BR112021022363A2 BR 112021022363 A2 BR112021022363 A2 BR 112021022363A2 BR 112021022363 A BR112021022363 A BR 112021022363A BR 112021022363 A BR112021022363 A BR 112021022363A BR 112021022363 A2 BR112021022363 A2 BR 112021022363A2
Authority
BR
Brazil
Prior art keywords
cells
manufacturing
compositions
methods
specific
Prior art date
Application number
BR112021022363A
Other languages
English (en)
Inventor
Murphy Kuksin Christina
Reddy Lenkala Divya
Duvalle Brown Flavian
Jessica Kohler
Huibert Van Den Berg Joost
M Van Buuren Marit
Noor Bakker
De Boer Renate
Ton Schumacher
Original Assignee
Biontech Us Inc
Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Us Inc, Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis filed Critical Biontech Us Inc
Publication of BR112021022363A2 publication Critical patent/BR112021022363A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464401—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Moulding By Coating Moulds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Casting Or Compression Moulding Of Plastics Or The Like (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)

Abstract

composições e métodos de fabricação de células t. a geração de células t específicas de antígeno por indução ou expansão ex vivo controlada pode proporcionar terapias de células t altamente específicas e benéficas. a presente descrição proporciona métodos de fabricação de células t e composições terapêuticas de células t que podem ser usadas para o tratamento de indivíduos com câncer e outras condições, doenças e distúrbios de terapia de células t específicas de antígenos pessoais.
BR112021022363A 2019-05-08 2020-05-07 Composições e métodos para fabricação de células t BR112021022363A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962845251P 2019-05-08 2019-05-08
PCT/US2020/031898 WO2020227546A1 (en) 2019-05-08 2020-05-07 T cell manufacturing compositions and methods

Publications (1)

Publication Number Publication Date
BR112021022363A2 true BR112021022363A2 (pt) 2022-03-22

Family

ID=73051205

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022363A BR112021022363A2 (pt) 2019-05-08 2020-05-07 Composições e métodos para fabricação de células t

Country Status (14)

Country Link
US (1) US20220280621A1 (pt)
EP (1) EP3965784A4 (pt)
JP (2) JP2022531474A (pt)
KR (1) KR20220044242A (pt)
CN (1) CN114096261A (pt)
AR (1) AR118859A1 (pt)
AU (1) AU2020268397A1 (pt)
BR (1) BR112021022363A2 (pt)
CA (1) CA3137037A1 (pt)
IL (1) IL287874A (pt)
MX (1) MX2021013608A (pt)
SG (1) SG11202112346WA (pt)
TW (2) TW202248419A (pt)
WO (1) WO2020227546A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
PL3591047T3 (pl) 2012-02-09 2022-12-05 Baylor College Of Medicine Mieszanki peptydowe do wytwarzania wielowirusowych ctl o szerokiej swoistości
EP4290238A2 (en) 2015-09-18 2023-12-13 Baylor College of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
US11948694B2 (en) * 2021-05-12 2024-04-02 Merative Us L.P. Controlling compartmental flows in epidemiological modeling based on mobility data
IL312121A (en) * 2021-10-15 2024-06-01 Biontech Us Inc Preparations and methods for the production of T cells
WO2023159088A1 (en) * 2022-02-15 2023-08-24 Marker Therapeutics, Inc. Compositions and methods for antigen-specific t cell expansion
CN117417886B (zh) * 2023-10-20 2024-05-14 广东壹加再生医学研究院有限公司 一种负载肿瘤抗原的树突状细胞激活的t淋巴细胞的培养方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004275871A1 (en) * 2003-09-25 2005-04-07 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
WO2006110582A1 (en) * 2005-04-08 2006-10-19 Xcyte Therapies, Inc. Compositions and methods for the treatment of burns and sepsis
DE102005046490A1 (de) * 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
WO2009045308A2 (en) * 2007-10-03 2009-04-09 Fred Hutchinson Cancer Research Center Enhanced generation of cytotoxic t-lymphocytes by il-21 mediated foxp3 suppression
EP2749639B1 (en) * 2012-02-10 2016-10-12 Hakushinkouseikai Foundation Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine
US11510971B2 (en) * 2015-08-10 2022-11-29 Toray Industries, Inc. Immune inducer
AU2016319126A1 (en) * 2015-09-10 2018-04-19 Affigen, Inc. Sequencing-directed selection of tumor theranostics
CN108473956B (zh) * 2015-10-09 2022-04-05 北昊干细胞与再生医学研究院有限公司 增强外源性施用t细胞的体内持久性和功效的方法、基因修饰的t细胞和方法以及使用方法
AU2018337960A1 (en) * 2017-09-20 2020-04-30 Neximmune, Inc. Cell compositions comprising antigen-specific T cells for adoptive therapy
SG11202004116QA (en) * 2017-11-08 2020-06-29 Biontech Us Inc T cell manufacturing compositions and methods

Also Published As

Publication number Publication date
US20220280621A1 (en) 2022-09-08
JP2022531474A (ja) 2022-07-06
TW202248419A (zh) 2022-12-16
MX2021013608A (es) 2022-01-31
KR20220044242A (ko) 2022-04-07
EP3965784A4 (en) 2023-06-21
AR118859A1 (es) 2021-11-03
CN114096261A (zh) 2022-02-25
WO2020227546A1 (en) 2020-11-12
TWI777160B (zh) 2022-09-11
EP3965784A1 (en) 2022-03-16
AU2020268397A1 (en) 2022-01-06
IL287874A (en) 2022-01-01
CA3137037A1 (en) 2020-11-12
JP2024038503A (ja) 2024-03-19
SG11202112346WA (en) 2021-12-30
TW202108761A (zh) 2021-03-01

Similar Documents

Publication Publication Date Title
BR112021022363A2 (pt) Composições e métodos para fabricação de células t
WO2019094642A8 (en) T cell manufacturing compositions and methods
MX2020004948A (es) Receptor de antígeno quimérico que selecciona como diana bcma, receptor de antígeno quimérico que selecciona como diana cd19 y terapias de combinación.
MX2019010972A (es) Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
MX2020009773A (es) Terapia de combinacion.
GT201200318A (es) Anticuerpos hacia gdf8 humano
NZ750974A (en) Antibody and checkpoint inhibitor combination therapy
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
BR112018007656A2 (pt) terapia de combinação para tratamento de doenças malignas
UY30097A1 (es) Usos terapeuticos de inhibidores de rtp801
MX2019012464A (es) Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl.
UY30525A1 (es) Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
AR109707A1 (es) Generación y uso en inmunoterapia adoptiva de células t de memoria tipo células madre
MX2019012465A (es) Terapia combinada con un conjugado de anticuerpo y farmaco anti-cd25.
MX2019003134A (es) Terapia de combinacion.
CY1123501T1 (el) Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος
BR112018007671A2 (pt) terapia de combinação para tratamento de malignidades
BR112022001148A2 (pt) Células imunes modificadas, composição farmacêutica, kit, uso de uma célula imune modificada e invenção de produto
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer
MX2019003235A (es) Metodos para tratar dermatitis atopica severa administrando un inhibidor de receptor de isoleucina-4.
BR112022005423A2 (pt) Interrupção de tecidos tumorais por alvejamento de proteína de ativação de fibroblasto (fap)
UY33219A (es) Cetoenoles cíclicos para terapias
BR112015031950A2 (pt) métodos para tratamento de câncer de ovário